Free tool
FAERS Monitor: Mirvaso
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 204708 or its brand name (Mirvaso, Brimonidine Tartrate). Reports on generic versions are filed under their own applications.
Reports
4,408
Serious
1,945
44% of reports
Hospitalization
758
Death reported
191
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- erythema578
- drug ineffective297
- eye pain289
- flushing285
- condition aggravated276
- product use issue256
- eye irritation227
- headache196
- fatigue194
- skin burning sensation179
- rosacea174
- vision blurred173
- dizziness172
- ocular hyperaemia172
- off label use155
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 28 |
| 2005 | 39 |
| 2006 | 36 |
| 2007 | 53 |
| 2008 | 37 |
| 2009 | 45 |
| 2010 | 55 |
| 2011 | 81 |
| 2012 | 77 |
| 2013 | 101 |
| 2014 | 334 |
| 2015 | 346 |
| 2016 | 234 |
| 2017 | 219 |
| 2018 | 200 |
| 2019 | 196 |
| 2020 | 301 |
| 2021 | 242 |
| 2022 | 259 |
| 2023 | 301 |
| 2024 | 333 |
| 2025 | 381 |
| 2026 | 510 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,751 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| rosaceaSignal | 174 | 185.1 | 159.5 | 30,495 |
| eye painSignal | 289 | 24.6 | 22.0 | 6,493 |
| eye irritationSignal | 227 | 18.9 | 16.6 | 3,823 |
| ocular hyperaemiaSignal | 172 | 17.4 | 15.0 | 2,631 |
| erythemaSignal | 578 | 13.5 | 12.5 | 6,696 |
| flushingSignal | 285 | 13.4 | 12.0 | 3,268 |
| skin burning sensationSignal | 179 | 11.9 | 10.3 | 1,787 |
| product use issueSignal | 256 | 6.5 | 5.8 | 1,197 |
| vision blurredSignal | 173 | 6.0 | 5.2 | 723 |
| condition aggravatedSignal | 276 | 4.3 | 3.9 | 714 |
| dizziness | 172 | 1.6 | 1.4 | 44 |
| headache | 196 | 1.5 | 1.3 | 32 |
| fatigue | 194 | 1.2 | 1.0 | 6 |
| drug ineffective | 297 | 1.1 | 1.0 | 2 |
| off label use | 155 | 0.8 | 0.7 | 4 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.